« Back
Home /
Ginsenoside F2

Ginsenoside F2

Item no.	HY-125848-1mg
Manufacturer	MedChem Express
CASRN	62025-49-4
Amount	1 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 20 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Mai TT, et al. Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells. Cancer Lett. 2012 Aug 28;321(2):144-53.
Smiles	C[C@@]([C@@]12C)(CC[C@@]3([H])C4(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO)([H])CC2)([H])[C@]3(CC[C@@H]4O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	62025-49-4
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; Autophagy; Endogenous Metabolite
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	785.01
Product Description	Ginsenoside F2, a metabolite from Ginsenoside Rb1, induces apoptosis accompanied by protective autophagy in breast cancer stem cells[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Autophagy; Metabolic Enzyme/Protease
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-125848-1mg-safety-datasheet.pdf